Abstract Context The European Association of Urology (EAU) Renal Cell Carcinoma (RCC)
Guideline Panel has prepared evidence-based guidelines and recommendations for the …

Context Considerable advances have been made in the first-line treatment of metastatic
renal cell carcinoma (mRCC), with immunotherapy-based combinations including …

PURPOSE To provide recommendations for the management of patients with metastatic
clear cell renal cell carcinoma (ccRCC). METHODS An Expert Panel conducted a systematic …

Renal cell carcinoma (RCC) is the most common and lethal tumor of the urological system.
Curative treatment of localized RCC includes nephrectomy, radio-ablation, and active …

Background Patients with metastatic renal cell carcinoma (mRCC) treated with systemic
therapy sometimes progress at limited sites. The best treatment approach for patients with …

Background Evidence-based guidelines for the management of systemic therapy–naïve
oligometastatic renal cell carcinoma (RCC) are lacking. Objective To evaluate the potential …

Purpose: High body mass index (BMI) may lead to improved immune-checkpoint blockade
(ICB) outcomes in metastatic clear cell renal cell carcinoma (mccRCC). However, BMI is a …

Simple Summary Stereotactic ablative radiation therapy (SAbR) is a safe and effective local
therapy for renal cell cancer (RCC) with emerging and evolving indications. In this review we …

Aim The action of immune checkpoint inhibition (ICI) largely depends on antibody-
dependent cellular phagocytosis (ADCP). We thus aim to develop ADCP-based ccRCC risk …

Simple Summary Immune checkpoint inhibitors (ICIs) have significantly changed the
treatment paradigm in metastatic renal cell carcinoma (mRCC) and brought an …